Aerie Pharmaceuticals (AERI) Getting Somewhat Favorable News Coverage, Analysis Finds

Media headlines about Aerie Pharmaceuticals (NASDAQ:AERI) have trended somewhat positive recently, according to Accern. The research firm identifies negative and positive press coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Aerie Pharmaceuticals earned a media sentiment score of 0.22 on Accern’s scale. Accern also gave headlines about the company an impact score of 46.1514308758338 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.

These are some of the news headlines that may have effected Accern Sentiment Analysis’s scoring:

How to Become a New Pot Stock Millionaire

Aerie Pharmaceuticals (NASDAQ:AERI) opened at $53.05 on Monday. The company has a debt-to-equity ratio of 0.91, a quick ratio of 10.09 and a current ratio of 10.09. The company has a market capitalization of $2,095.10, a P/E ratio of -13.03 and a beta of 0.98. Aerie Pharmaceuticals has a twelve month low of $38.14 and a twelve month high of $66.60.

Aerie Pharmaceuticals (NASDAQ:AERI) last posted its quarterly earnings data on Wednesday, February 28th. The company reported ($1.38) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.21) by ($0.17). research analysts expect that Aerie Pharmaceuticals will post -3.62 EPS for the current year.

A number of analysts have recently weighed in on AERI shares. BidaskClub raised Aerie Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Tuesday, December 5th. Cantor Fitzgerald set a $77.00 target price on Aerie Pharmaceuticals and gave the company a “buy” rating in a report on Monday, December 18th. Canaccord Genuity set a $73.00 target price on Aerie Pharmaceuticals and gave the company a “buy” rating in a report on Monday, December 18th. Mizuho restated a “buy” rating and set a $87.00 target price on shares of Aerie Pharmaceuticals in a report on Tuesday, December 19th. Finally, Zacks Investment Research upgraded Aerie Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Monday, January 22nd. Three investment analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. Aerie Pharmaceuticals has a consensus rating of “Buy” and a consensus target price of $78.75.

ILLEGAL ACTIVITY WARNING: This piece was posted by Ticker Report and is owned by of Ticker Report. If you are reading this piece on another website, it was copied illegally and reposted in violation of United States & international copyright and trademark legislation. The original version of this piece can be read at https://www.tickerreport.com/banking-finance/3301092/aerie-pharmaceuticals-aeri-getting-somewhat-favorable-news-coverage-analysis-finds.html.

Aerie Pharmaceuticals Company Profile

Aerie Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s product candidates include Rhopressa (netarsudil ophthalmic solution) 0.02% (Rhopressa), and Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% (Roclatan).

Insider Buying and Selling by Quarter for Aerie Pharmaceuticals (NASDAQ:AERI)

Receive News & Ratings for Aerie Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Analyzing Dicks Sporting Goods  and Barnes & Noble Education
Analyzing Dicks Sporting Goods and Barnes & Noble Education
FuckToken Price Reaches $0.0166 on Major Exchanges
FuckToken Price Reaches $0.0166 on Major Exchanges
Quantum  versus Western Digital  Financial Survey
Quantum versus Western Digital Financial Survey
Comparing Shanghai Petrochemical  & Its Peers
Comparing Shanghai Petrochemical & Its Peers
Sanderson Farms, Inc.  Receives $123.00 Consensus Target Price from Analysts
Sanderson Farms, Inc. Receives $123.00 Consensus Target Price from Analysts
Hain Celestial Group  Receives $39.48 Average PT from Analysts
Hain Celestial Group Receives $39.48 Average PT from Analysts


© 2006-2018 Ticker Report. Google+.